This context was mimicked by examining release from cytostatic doses of the dual ErbB inhibitor, lapatinib, in TM15 clone 6 (TM15c6) cells derived from an Erbb2-amplified tumor of a PMMTV-Cre;Erbb2+/V660E knockin mouse29–31. Here, ERBB2 is linked to neoplasm.